Valuation: Sionna Therapeutics, Inc.

Market Cap 222M 197M 184M 168M 316M 21.34B 319M 2.23B 863M 10.91B 833M 815M 35.01B P/E 2026 *
-2.03x
P/E 2027 * -2.13x
Enterprise Value 66.6M 59.18M 55.23M 50.34M 94.95M 6.4B 95.83M 668M 259M 3.27B 250M 245M 10.5B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.12%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Sionna Therapeutics, Inc.

1 day-3.73%
1 week-6.12%
Current month-6.65%
1 month-32.83%
3 months-88.84%
6 months-87.87%
Current year-88.07%
1 week 4.86
Extreme 4.86
5.34
1 month 4.86
Extreme 4.86
8.54
Current year 4.01
Extreme 4.01
54.97
1 year 4.01
Extreme 4.01
54.97
3 years 4.01
Extreme 4.01
54.97
5 years 4.01
Extreme 4.01
54.97
10 years 4.01
Extreme 4.01
54.97
Manager TitleAgeSince
Corporate Officer/Principal - 2019-07-31
Corporate Officer/Principal - 2019-07-31
Chief Executive Officer 55 2021-04-30
Director TitleAgeSince
Director/Board Member 51 2019-11-30
Director/Board Member 44 2019-11-30
Director/Board Member 52 2020-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26 Free

General Counsel

262,545 0.5807%
9/17/26 Free

Chief Financial Officer

425,417 0.9409%
9/17/26 Free

Chief Technology Officer

411,400 0.9099%
Change 5-day change 1-year change 3-year change Capi.($)
-3.73%-6.12%-83.24% - 222M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.58%-1.14%+40.63%+120.28% 39.08B
Weighted average by Cap. +0.12%-0.84%+58.68%+129.91%

Financials

2026 *2027 *
Net sales - -
Net income -112M -99.54M -92.9M -84.68M -160M -10.77B -161M -1.12B -436M -5.51B -421M -411M -17.67B -114M -101M -94.36M -86.01M -162M -10.94B -164M -1.14B -443M -5.59B -427M -418M -17.95B
Net Debt -155M -138M -129M -117M -222M -14.94B -224M -1.56B -604M -7.64B -583M -571M -24.51B -231M -205M -191M -174M -329M -22.18B -332M -2.32B -897M -11.34B -866M -847M -36.39B
Logo Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Employees
59
Date Price Change Volume
26-10-02 US$4.910 -3.73% 1,160,195
26-10-01 US$5.100 -3.04% 1,059,874
26-09-30 US$5.260 +2.14% 1,157,751
26-09-29 US$5.150 +0.59% 797,862
26-09-28 US$5.120 -2.10% 775,817
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
4.910USD
Average target price
21.00USD
Spread / Average Target
+327.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SION Stock